Annexon (ANNX) Stock Forecast, Price Target & Predictions
ANNX Stock Forecast
Annexon stock forecast is as follows: an average price target of $14.00 (represents a 128.76% upside from ANNX’s last price of $6.12) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ANNX Price Target
The average price target for Annexon (ANNX) is $14.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 128.76% upside from ANNX's last price of $6.12.
ANNX Analyst Ratings
According to 5 Wall Street analysts, Annexon's rating consensus is 'Buy'. The analyst rating breakdown for ANNX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Annexon Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 05, 2024 | Derek Archila | Wells Fargo | $14.00 | $5.99 | 133.72% | 128.76% |
| May 15, 2024 | Derek Archila | Wells Fargo | $10.00 | $4.82 | 107.47% | 63.40% |
| Apr 01, 2024 | Derek Archila | Wells Fargo | $12.00 | $7.17 | 67.36% | 96.08% |
The latest Annexon stock forecast, released on Jun 05, 2024 by Derek Archila from Wells Fargo, set a price target of $14.00, which represents a 133.72% increase from the stock price at the time of the forecast ($5.99), and a 128.76% increase from ANNX last price ($6.12).
Annexon Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $6.12 | $6.12 | $6.12 |
| Upside/Downside | -100.00% | -100.00% | 96.08% |
In the current month, the average price target of Annexon stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Annexon's last price of $6.12. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 01, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 06, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 26, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 05, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 15, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Apr 01, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Dec 21, 2023 | Bank of America Securities | - | Buy | Upgrade |
| Sep 16, 2022 | Jefferies | - | Buy | Initialise |
| Nov 30, 2021 | H.C. Wainwright | - | Buy | Initialise |
Annexon's last stock rating was published by Cowen & Co. on Oct 23, 2024. The company gave ANNX a "Buy" rating, the same as its previous rate.
Annexon Financial Forecast
Annexon Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Annexon's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANNX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Annexon EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ANNX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Annexon's previous annual EBITDA (undefined) of $NaN.
Annexon Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-40.58M | $-39.65M | $-38.72M | $-36.85M | $-38.21M | $-36.12M | $-29.86M |
| High Forecast | $-40.58M | $-39.65M | $-38.72M | $-33.04M | $-35.27M | $-36.12M | $-29.86M |
| Low Forecast | $-40.58M | $-39.65M | $-38.72M | $-40.66M | $-42.62M | $-36.12M | $-29.86M |
| Surprise % | - | - | - | - | - | - | - |
Annexon's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANNX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Annexon SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Annexon's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ANNX last annual SG&A of $NaN (undefined).
Annexon EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.26 | $-0.27 | $-0.26 | $-0.23 |
| High Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.24 | $-0.25 | $-0.26 | $-0.23 |
| Low Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.29 | $-0.30 | $-0.26 | $-0.23 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Annexon's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANNX previous annual EPS of $NaN (undefined).
Annexon Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.68 | $70.00 | 10194.12% | Buy |
| INAB | IN8bio | $0.34 | $14.00 | 4017.65% | Buy |
| XFOR | X4 Pharmaceuticals | $0.40 | $3.67 | 817.50% | Buy |
| INZY | Inozyme Pharma | $3.13 | $14.67 | 368.69% | Buy |
| CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | - |
| IMMX | Immix Biopharma | $1.59 | $7.00 | 340.25% | Buy |
| RLAY | Relay Therapeutics | $5.11 | $19.40 | 279.65% | Buy |
| ZURA | Zura Bio | $3.16 | $10.00 | 216.46% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.40 | $7.00 | 191.67% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| GPCR | Structure Therapeutics | $34.17 | $92.40 | 170.41% | Buy |
| ANNX | Annexon | $6.12 | $14.00 | 128.76% | Buy |
| CGEM | Cullinan Oncology | $13.86 | $31.50 | 127.27% | Buy |
| RCUS | Arcus Biosciences | $15.70 | $33.00 | 110.19% | Buy |
| WVE | Wave Life Sciences | $13.67 | $22.14 | 61.96% | Buy |
| BPMC | Blueprint Medicines | $88.69 | $109.71 | 23.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.76 | $5.33 | 11.97% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |